Capricor Therapeutics (NASDAQ:CAPR) Coverage Initiated at Alliance Global Partners

Alliance Global Partners initiated coverage on shares of Capricor Therapeutics (NASDAQ:CAPR - Free Report) in a research note released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $20.00 price target on the biotechnology company's stock.

Several other equities research analysts also recently commented on the company. B. Riley assumed coverage on Capricor Therapeutics in a report on Thursday, June 26th. They issued a "buy" rating and a $21.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Jones Trading lowered their price objective on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday, June 25th. Wall Street Zen downgraded shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, Roth Capital reiterated a "buy" rating and set a $31.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, June 17th. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $32.22.

Capricor Therapeutics Stock Down 2.3%

Capricor Therapeutics stock traded down $0.23 during trading hours on Monday, hitting $9.70. The stock had a trading volume of 1,155,462 shares, compared to its average volume of 1,969,453. The stock's 50-day moving average price is $10.76 and its 200-day moving average price is $12.29. The stock has a market capitalization of $443.10 million, a P/E ratio of -6.83 and a beta of 0.82. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The firm had revenue of $2.73 million for the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.42%. During the same period last year, the business earned ($0.31) EPS. On average, research analysts expect that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Institutional Trading of Capricor Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CAPR. Rhumbline Advisers grew its stake in shares of Capricor Therapeutics by 44.4% during the 4th quarter. Rhumbline Advisers now owns 46,083 shares of the biotechnology company's stock valued at $636,000 after acquiring an additional 14,169 shares during the period. New York State Common Retirement Fund increased its stake in shares of Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 5,000 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Capricor Therapeutics by 32.6% during the 4th quarter. Bank of New York Mellon Corp now owns 84,027 shares of the biotechnology company's stock valued at $1,160,000 after purchasing an additional 20,638 shares during the period. Oppenheimer & Co. Inc. raised its position in shares of Capricor Therapeutics by 52.4% during the 4th quarter. Oppenheimer & Co. Inc. now owns 104,231 shares of the biotechnology company's stock valued at $1,438,000 after purchasing an additional 35,823 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Capricor Therapeutics by 51.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company's stock valued at $1,536,000 after buying an additional 37,868 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.